Figures
Abstract
Background
Brazil has at least 800,000 HTLV-1 infected individuals. HTLV-1 can be transmitted via sexual intercourse, contact with blood and from mother to child, mainly by breastfeeding. Treatments for the high morbidity/mortality associated diseases (ATL and HAM/TSP) are limited, therefore, infection prevention is of utmost importance. However, antenatal screening is not routinely performed in Brazil. A lack of data regarding the number of individuals infected via breastfeeding impairs the development of government policies. The objective is to estimate the number of HTLV-1 infections occurring annually due to mother to child transmission (MTCT) in Brazil, nationally and regionally.
Methodology
To estimate HTLV-1 MTCT in Brazil the following variables are modelled: number of births, prevalence of HTLV-1 infection in pregnant women, breastfeeding duration rate and transmission risk according to breastfeeding period. The number of cases of HAM/TSP and ATL attributable to MTCT are also estimated.
Principal findings
In 2008, there were 2,934,828 live births in Brazil. HTLV prevalence in pregnant women in Brazil ranges between 0.1–1.05% by region. An estimated 16,548 HTLV-1 infected women are pregnant each year. According to the breastfeeding pattern and HTLV-1 prevalence of each region there are an estimated 3,024 new cases of HTLV-1 infection due to MTCT annually of which 2,610 are preventable through infant feeding advice. These 3,024 transmissions will result in 120–604 cases of ATL and 8–272 of HAM/TSP. North-East region comprises the high number of MTCT cases, followed by South-East.
Author summary
The human T-cell lymphotropic virus type 1 (HTLV-1) causes lifelong infection in humans. Although most infected individuals remain asymptomatic HTLV-1 causes severe disease in at least 5% of carriers. In the present study we estimate the number of HTLV-1 infections that occur annually due to mother to child transmission (MTCT) in Brazil and within its regions. The high number of estimated cases due to MTCT (3,024) which will give rise in adult life to HTLV-1associated diseases suggest the importance of performing HTLV-1 antenatal screening in Brazil to reduce the dissemination of this infection and to thus prevent a blood cancer to which most individuals succumb within 8 months of presentation and in others a disabling disease of the spinal cord.
Citation: Rosadas C, Malik B, Taylor GP, Puccioni-Sohler M (2018) Estimation of HTLV-1 vertical transmission cases in Brazil per annum. PLoS Negl Trop Dis 12(11): e0006913. https://doi.org/10.1371/journal.pntd.0006913
Editor: Benjamin Althouse, Institute for Disease Modeling, UNITED STATES
Received: June 24, 2018; Accepted: October 11, 2018; Published: November 12, 2018
Copyright: © 2018 Rosadas et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: The authors received no specific funding for this work.
Competing interests: The authors have declared that no competing interests exist.
Introduction
The human T-cell lymphotropic virus type 1 (HTLV-1) infects at least 5–10 million individuals throughout the world. Brazil has approximately 800,000 carriers [1]. This virus can be transmitted via sexual intercourse, contact with infected blood and from mother to child, mainly through breastfeeding[1]. Most infected individuals (>90%) remain lifelong asymptomatic carriers but are infectious, perpetuating HTLV-1 transmission. However, the diseases associated with this infection, such as HTLV-1-associated myelopathy / tropical spastic paraparesis (HAM/TSP) and adult T cell leukaemia (ATL) have high morbidity and mortality[1–3]. The life-expectancy of ATL at 8 months is one of the shortest of all malignancies. Half of all patients who develop HAM/TSP become wheelchair dependent. Treatment for these conditions remain limited.
HTLV-1 infection may be detected using screening tests such as enzyme-linked immunosorbent assay (ELISA). However, confirmatory and typing tests are mandatory to conclude the diagnosis. Western blot (WB) and the HTLV-1 proviral DNA detection by polymerase chain reaction (PCR) are considered confirmatory tests [4–6].
To reduce HTLV-1 transmission in Brazil, since 1993 blood donations are tested before transfusion[7]. However, antenatal screening is not routinely performed by the national health system of Brazil (Sistema Único de Saúde, SUS). Mother-to-child transmission (MTCT) is responsible for maintaining the virus for several generations in the same family [8,9].
Several studies have demonstrated that a reduction in the number of mothers breast-feeding and a shortening of the breast-feeding period decreased the MTCT by about 80% [10,11]. This is evident in Japan, which implemented a successful program to prevent HTLV-1 vertical transmission in some regions [12] and now has a national programme.
Lack of data regarding the number of individuals infected via breastfeeding impairs the development and implementation of government policies. In 2016, for example, in Brazil, there were 87 new diagnoses of HIV infection reported in children under 5 years[13]. However, this number is not known for HTLV infection.
Our aim is to estimate the number of HTLV-1 infections that occur annually due to mother to child transmission (MTCT) in Brazil.
Methods
For the estimation of the number of HTLV-1 cases due to MTCT per year in Brazil, the following variables were used: number of births in Brazil and its regions, prevalence of HTLV-1 infection in pregnant women in the country, breastfeeding duration rate and transmission risk according to breastfeeding period. We also estimated the number of HAM/TSP and ATL cases due to MTCT according to the lifetime risk of each disease. The number of births in Brazil and the breastfeeding duration rate were acquired from Health Ministry of Brazil data.
HTLV prevalence in pregnant woman from Brazil
To determine the prevalence of HTLV-1 infection in pregnant women in Brazil, a literature review was performed according to recommendations established by Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA)[14]. The search terms “HTLV”, “prevalence” and “Brazil” were used in Pubmed, Scopus and Scielo databases. The search was conducted in October 2017 and there was no restriction regarding the publication year. Only articles written in English, Spanish or Portuguese were considered. Books or book chapters, comments, editorials and reviews were not included.
The following inclusion criteria were: 1) studied population includes Brazilian pregnant women; 2) it provides measures of prevalence; 3) studies used confirmatory tests for HTLV-1 infection, such as WB or molecular assays, such as PCR. The exclusion criteria were: 1) studies that did not provide prevalence; 2) studied population was not pregnant women; 3) pregnant women were not from Brazil; 4) the study performed only screening test for HTLV infection.
For this systematic review no protocol was registered, and no quality scoring system was applied.
Data regarding the number of analysed samples, year of study publication, HTLV-1 test method, Brazilian state, prevalence of HTLV in pregnant women were extracted from the selected studies.
Breastfeeding duration rates in Brazil
In 2008, a large study regarding the prevalence of breastfeeding within Brazil was performed by Brazilian Health Ministry. In this study, the prevalence of breastfeeding was determined from 30 days until 1 year after birth and it included analysis per country region and by Brazilian state [15]. These data were acquired and used in the present study (Table 1).
[15].
Estimation of HTLV-1 Mother-to-Child transmission cases
To estimate HTLV-1 MTCT cases in Brazil we used the methodology described in Malik et al. 2018. The HTLV-1 transmission risk according to breastfeeding period assumed were those reported by Takezaki and colleagues [16]. A line of best fit was applied, and an equation derived from which come the estimates of transmission for 3 monthly increments (Fig 1). The transmission risks used in the manuscript were: 1.5 months–zero risk; 4.5 months—1.9%; 7.5m - 6.03%; 10.5m - 10.1%; 13.5m - 14.16%; 16.5m - 18.24%; 19.5m - 22.3%; 22.5m - 26.3%; 25.5m - 30% and up to 36m - 44.69% (Fig 1). These estimates are consistent with data from the region including studies from French Guyana [17] with a transmission rate of 10.6% in children breast-fed for a mean of 12 months and Jamaica [18] with a transmission of 32% who breast-fed for longer than 12 months. Finally, a very recent study from Brazil [19], demonstrated that the rate of transmission was 23.8% on long term breastfeeding (> 12 months) and 50% when breastfeeding duration was 24–36 months. These data plus the estimate from Takahashi that breast-feeding for less than 6 months was associated with 4.4% transmission (in Japan) leads us to believe that the attributed risk that we have used is consistent with all published data and errs towards a more conservative end of the range. As the literature indicates, up to three months breastfeeding confers zero risk of HTLV-1 transmission due to breast-feeding[13].
A) Model used to calculate the number of breastfeeding women over time in Brazil: Breastfeeding duration (days) against HTLV-1 transmission; B-F) Model used to evaluate the HTLV-1 transmission risk according to breastfeeding duration rates in the different Brazilian regions: B) North; C) North East; D) Midwest; E) South East; F) South.
In a similar process, by retrieving published data on breastfeeding rates against time for each region of Brazil [12] (Table 1), a line of best fit was derived using Excel. The resulting exponential decay equation was used to extrapolate breastfeeding rates for a period of 0 to 3 years. Three years was deemed the maximum breastfeeding duration (Fig 1).
By multiplying the number of breastfeeding women in three-month periods from 0 to 3 years, midpoint viral transmission rate for the respective period and the seroprevalence of HTLV-1 amongst pregnant women in the population (Table 2); the number of HTLV-1 mother to child transmission cases from breastfeeding was determined.
For completeness, a 2.5 percent risk of mother to child transmission from sources other than breastfeeding is incorporated in the analysis [13]. This was calculated by multiplying 2.5 percent with the product of the number of births annually multiplied by the seroprevalence of HTLV-1 amongst pregnant women (Fig 1).
Estimation of ATL and HAM/TSP risk
HAM/TSP and ATL development rate comprises the proportion of individuals who develop those diseases following HTLV-1 infection. The lifetime risk of HAM varies between 0.25% to 3%. However, in Brazil, some studies showed a high risk for HAM/TSP onset [20]. The incidence in Tanajura et al. (2015) of 1.47% in 414 cases over a mean of 3 years equates to a 9% life-time risk. As it is not known whether infection in infancy or adult life has any impact on this risk, lifetime risks of 0.25%, 3% and 9% were imputed. For analysis purpose, ATL development rate was assumed to be 4%-20%, according to previous studies. While the ATL overall rate is estimated to be approximately 4% among all HTLV-1 infected individuals, it is known that ATL development is associated with childhood infection. Considering also that up to 85% of HTLV infections occurs in adult life, the risk of ATL development after vertical transmission should be adjusted, therefore, we considered a scenario with an upper limit of 20%. There are no data regarding ATL incidence in Brazil.
Results
The systematic review regarding HTLV prevalence in pregnant woman from Brazil identified 565 studies. Fig 2 represents the flow chart for study selection. Table 2 shows the included studies and the main findings [21–35]. The prevalence of HTLV-1 infection in pregnant women from Brazil varied between 0–1.05%. Due to the high diversity in HTLV prevalence observed between different regions of Brazil (Fig 3), we estimated the number of cases due to MTCT for each region. For this analysis, studies with less than 1000 individuals were excluded. For the south region, we assume the lowest HTLV prevalence observed among the different states in the country (0.1%), since there are no data available regarding the HTLV prevalence in pregnant women in this region. Considering the data from each of Brazil`s regions, we estimate that there are 16,548 pregnant women in Brazil infected with HTLV-1 each year (Table 3). However, if we just assume the highest and lowest HTLV-1 prevalence reported in pregnant women in Brazil (0.1–1.05%), the estimated number varies between 2,935–30,815 infected pregnant women/year.
The flow diagram indicates the numbers of studies reviewed in preparation of the current systematic review of HTLV prevalence in pregnant woman from Brazil. Adapted from [14].
The map was created with Paint 3D Windows and Adobe Photoshop CC 2018, using the open source map available at https://commons.wikimedia.org/wiki/Atlas_of_the_world.
In 2008, there were 2,934,828 births in Brazil. A summary of the findings for each region of Brazil is presented in Table 3. The North-East region contributes with the high number of HTLV-1 MTCT cases, followed by South-East region. Factoring in breast-feeding patterns a total of 2,610 new HTLV-1 infections per year through breastfeeding is estimated in the country. Moreover, 414 new vertical infections should occur annually through delivery and could not be avoided using breast milk substitutes. Therefore, the estimated total number of cases of HTLV-1 infections due to MTCT in Brazil is 3,024 per annum.
Regarding HTLV associated diseases, supposing 4–20% and 3% (0.25–9%) the risk of ATL and HAM/TSP development respectively, 120–604 ATL and 91 cases (8–272) HAM/TSP cases should occur in the future due to MTCT each year.
Discussion
HTLV-1 infection and its associated diseases remain neglected [36]. While ATL is associated with high mortality and poor outcome, HAM/TSP is a disabling chronic disease which causes an important impairment in the patient`s quality of life. There is no cure available, only symptomatic treatment, increasing the costs to the health system and causing a negative impact on the patient`s life. Therefore, prevention is the best way to control the disease. For the implementation of effective measures to control the virus transmission, it is necessary to understand the scenario of each location. The determination of the number of new cases that occur per year due to mother to child transmission in Brazil is essential and can serve as a guide for the development and implementation of public health policies aimed at controlling this infection.
To estimate the number of new cases of HTLV infections due to MTCT in Brazil we used the transmission risk rates observed in Japan as they are very robust. A recent paper from Brazil, obtained very similar rates of those that were used, confirming that they are suitable for this study. Different factors, such as HTLV proviral load and coinfections can influence the MTCT risk. For example, in Peru, Strongyloides infection results in an increased rate of MTCT (31%) [37,38]. Early introduction of mixed feeding may also change the level of transmission. However, it is important to note that early introduction of breastfeeding is also a reality in São Paulo [15], where the study of Paiva et al (2018)[19] was conducted and observed transmission rates similar to those that were used in this study. Therefore, it is unlikely that will influence the predicted transmission rates.
The present analysis indicates that a large number of new cases of HTLV infections due to mother to child transmission in Brazil occur each year. When comparing with other diseases that are currently included in prenatal and neonatal screening, such as HIV, the size of the problem becomes more evident. Beside this, we also calculate that antenatal screening to identify infected mothers who would be advised regarding the risk of transmission and associated diseases and potentially to avoid or limit breastfeeding, would lead to the prevention of 104–522 cases of ATL and 6–235 cases of HAM/TSP which result from vertical transmission each year (excluding 16–82 ATL and 2–37 HAM/TSP cases, that are considered associated with the residual transmission). These diseases present high morbidity and mortality. However, even apparently asymptomatic infection has a negative impact on the life of HTLV-1 seropositive patients. Decreased quality of life, increased incidence of depression and anxiety among asymptomatic individuals diagnosed with HTLV infection has been demonstrated and are not necessarily a consequence of being informed of the diagnosis [39–41]. In Brazil, this can be exacerbated by the lack of care in public health that HTLV infected patients need to face as clearly reported by Zihlmann and colleagues (2012) [42].
In this study, to estimate the number of individuals that will develop clinical manifestations resulting from HTLV infection we used the range described in the literature. The risk of HAM/TSP development after vertical transmission is not known. However, there are many reports that HAM/TSP can occur after mother to child transmission [43–48]. Although the rate of HAM/TSP that seems more applicable for the country is 3%, in this study a range was used, includging the 0.25% calculated for Japan [49]. Recent studies indicate that Brazil may have a higher percentage of HAM/TSP and other neurological diseases among infected individuals [20]. In fact, Tanajura and colleagues (2015) followed a cohort of asymptomatic individuals from Brazil for up to eight years reported a high incidence of neurological disorders (up to 30%) and 1.5% incidence after 3 years. In the other hand, there are limited data on ATL in Brazil [44]. Therefore, we used the ATL life-time risk of all carriers (4%) as the conservative estimation. However, it is recognised that only those carriers who were infected during the perinatal and infancy period are at risk of ATL and is also known that approximately 80% of HTLV-1 infections are acquired in adult life. Therefore, the risk that infected infants will at some point in their adult life develop ATL should be as higher as 20% [50]. The present study also did not consider other clinical manifestation that can affect HTLV-1 infected individuals, such as infective dermatitis, uveitis, Sjögren's syndrome, Hashimoto's thyroiditis, and Graves' disease [6,51] or the impact of HTLV-1 infection on other infections, most notably Strongyloidiasis, tuberculosis and Hepatitis C.
Antenatal screening would also detect, and with the same intervention could also prevent mother to child transmission of, HTLV-2. This virus type was not included in the study, since the data regarding its prevalence are scarce, especially in pregnant women.
It is also worth noting that, preventing the occurrence of a single new case, it is possible to inhibit the transmission chain of this individual, blocking virus maintenance for generations and intra-family dissemination, a fact commonly observed in HTLV infection [8,9,52–54]. In Salvador, 32.56% of the family members of the HTLV-1 seropositive women were positive, including children from previous pregnancy [55]. Therefore, the identification of a pregnant woman may be considered just a tip of the iceberg and reinforce the importance of strategies of active surveillance once the infection is diagnosed in an individual.
In Japan, a country with a high HTLV prevalence, a nationwide MTCT prevention program was implemented in 2011. To prevent the vertical transmission, the HTLV-1 seropositive pregnant women are recommended to use three feeding methods: formula feeding, short term breast-feeding (up to 3 months), and feeding with thawed frozen milk. It is noteworthy that infection may occur in the mother after the antenatal screening therefore, the period in which the screening is made may be relevant and it perhaps it should be performed later into the pregnancy. However, the cost of this would be much higher than adding HTLV-1 to the existing screening process. Incident maternal infection during the breast-feeding period has not be considered in this analysis.
Antenatal screening implementation is an important tool to prevent HTLV dissemination. In 1987, the Nagasaki Prefecture in Japan, implemented the ATLL Prevention Program Nagasaki, and the avoidance of breastfeeding by HTLV infected mother resulted in an important reduction of HTLV-1 MTCT from 20.3% to 2.5%, confirming the importance of antenatal screening in disease control [10,56]. Similar results were observed in other Japanese regions [12,57].
It is important to highlight that avoidance of breastfeeding may be harmful, mainly in low-income regions, as early weaning could result in an increased infant mortality and in the number of diarrheal diseases events [58]. Seropositive mothers should have multidisciplinary follow-up to ensure that they receive adequate and necessary information and support.
Although antenatal HTLV-1 screening is performed in some Brazilian’s cities/states, such as Salvador, the city with the highest reported HTLV-1 prevalence, it is not included among the tests that are currently offered for pregnant woman by the Brazilian health system.
Finally, this study showed that the non-implementation of the test in the antenatal routine performed by SUS cannot be justified on the grounds of scarcity of infected individuals, since the national neonatal screening program screens for diseases such as, cystic fibrosis and phenylketonuria that affect approximately 1,250 and 1,225 inhabitants in Brazil respectively [59,60].
Therefore, we conclude that HTLV-1/2 antenatal screening should be implemented in the routine evaluation of pregnant women from Brazil that is offered by the national health system in order to ensure that which is established in the Brazilian Constitution: health as a universal right.
References
- 1. Gessain A, Cassar O. Epidemiological Aspects and World Distribution of HTLV-1 Infection. Front Microbiol. 2012;3: 388. pmid:23162541
- 2. Nose H, Saito M, Usuku K, Sabouri AH, Matsuzaki T, Kubota R, et al. Clinical symptoms and the odds of human T-cell lymphotropic virus type 1-associated myelopathy/ tropical spastic paraparesis (HAM/TSP) in healthy virus carriers: application of best-fit logistic regression equation based on host genotype, age, and proviru. J Neurovirol. 2006;12: 171–7. pmid:16877298
- 3. Castro-Costa CM, Araújo AQC, Barreto MM, Takayanagui OM, Sohler MP, da Silva ELM, et al. Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM). AIDS Res Hum Retroviruses. 2006;22: 931–5. pmid:17067261
- 4. Ishihara K, Inokuchi N, Tsushima Y, Tsuruda K, Morinaga Y, Hasegawa H, et al. Relevance of molecular tests for HTLV-1 infection as confirmatory tests after the first sero-screening. J Immunoassay Immunochem. 2014;35: 74–82. pmid:24063618
- 5. Santos FLN, Lima FWDM. Epidemiologia, fisiopatogenia e diagnóstico laboratorial da infecção pelo HTLV-I Epidemiology, physiopathogenesis and laboratorial diagnosis of the HTLV-I infection. J Bras Patol Med Lab. 2005;41: 105–116.
- 6. Gonçalves DU, Proietti FA, Ribas JGR, Araújo MG, Pinheiro SR, Guedes AC, et al. Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev. 2010;23: 577–89. pmid:20610824
- 7.
Ministério da Saúde do Brasil. Portaria 1376 de 19/11/1993—Ministério da Saúde. 1993.
- 8. Catalan-soares B, Barbosa-stancioli EF, Alcantara LCJ, Carneiro-proietti ABDEF, Martins ML, Namen-lopes MS, et al. HTLV-2 Horizontal and Vertical Transmission in a Family from a Brazilian Urban Area: Seroepidemiological, Clinical and Molecular Study. 2005;21: 521–526.
- 9. Frutos MC, Gastaldello R, Balangero M, Remondegui C, Blanco S, Otsuki K, et al. Silent dissemination of HTLV-1 in an endemic area of Argentina. Epidemiological and molecular evidence of intrafamilial transmission. PLoS One. Public Library of Science; 2017;12: e0174920. pmid:28384180
- 10. Hino S, Katamine S, Miyata H, Tsuji Y, Yamabe T, Miyamoto T. Primary prevention of HTLV-1 in Japan. Leukemia. 1997;11 Suppl 3: 57–9. Available: http://www.ncbi.nlm.nih.gov/pubmed/9209297
- 11. Hino S. Establishment of the milk-borne transmission as a key factor for the peculiar endemicity of human T-lymphotropic virus type 1 (HTLV-1): the ATL Prevention Program Nagasaki. Proc Jpn Acad Ser B Phys Biol Sci. The Japan Academy; 2011;87: 152–66. pmid:21558754
- 12.
Kashiwagi K, Furusyo N, Nakashima H, Kubo N, Kinukawa N, Kashiwagi S, et al. A DECREASE IN MOTHER-TO-CHILD TRANSMISSION OF HUMAN T LYMPHOTROPIC VIRUS TYPE I (HTLV-I) IN OKINAWA, JAPAN. Available: http://www.ajtmh.org/docserver/fulltext/14761645/70/2/0700158.pdf?expires=1510569303&id=id&accname=guest&checksum=5742246458FC9990F8100AF306DBDE71
- 13.
Ministério da Saúde do Brasil. Boletim Epidemiológico HIV/AIDS [Internet]. 2015. Available: file:///C:/Users/Carolina/Downloads/boletim_epidemiologico_hivaids_-_2015 (1).pdf
- 14. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group TP. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. Public Library of Science; 2009;6: e1000097. pmid:19621072
- 15.
Brasil M da S do. II Pesquisa de Prevalência de Aleitamento Materno nas Capitais Brasileiras e Distrito Federal. 2009; Available: http://bvsms.saude.gov.br/bvs/publicacoes/pesquisa_prevalencia_aleitamento_materno.pdf
- 16. Takezaki T, Tajima K, Ito M, Ito S, Kinoshita K, Tachibana K, et al. Short-term breast-feeding may reduce the risk of vertical transmission of HTLV-I. The Tsushima ATL Study Group. Leukemia. 1997;11 Suppl 3: 60–2. Available: http://www.ncbi.nlm.nih.gov/pubmed/9209298
- 17. Ureta-Vidal A, Angelin-Duclos C, Tortevoye P, Murphy E, Lepère J-F, Buigues R-P, et al. Mother-to-child transmission of human T-cell-leukemia/lymphoma virus type I: Implication of high antiviral antibody titer and high proviral load in carrier mothers. Int J Cancer. Wiley-Blackwell; 1999;82: 832–836. pmid:10446450
- 18. Wiktor SZ, Pate EJ, Rosenberg PS, Barnett M, Palmer P, Medeiros D, et al. Mother-to-child transmission of human T-cell lymphotropic virus type I associated with prolonged breast-feeding. J Hum Virol. 1997;1: 37–44. Available: http://www.ncbi.nlm.nih.gov/pubmed/10195229 pmid:10195229
- 19. Paiva AM, Assone T, Haziot MEJ, Smid J, Fonseca LAM, Luiz O do C, et al. Risk factors associated with HTLV-1 vertical transmission in Brazil: longer breastfeeding, higher maternal proviral load and previous HTLV-1-infected offspring. Sci Rep. Nature Publishing Group; 2018;8: 7742. pmid:29773807
- 20. Tanajura D, Castro N, Oliveira P, Neto A, Muniz A, Carvalho NB, et al. Neurological Manifestations in Human T-Cell Lymphotropic Virus Type 1 (HTLV-1)-Infected Individuals Without HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis: A Longitudinal Cohort Study. Clin Infect Dis. 2015;61: 49–56. pmid:25820277
- 21. Moura AA, Mello MJG de, Correia JB. Prevalence of syphilis, human immunodeficiency virus, hepatitis B virus, and human T-lymphotropic virus infections and coinfections during prenatal screening in an urban Northeastern Brazilian population. Int J Infect Dis. 2015;39: 10–15. pmid:26255887
- 22. Monteiro DLM, Taquette SR, Sodré Barmpas DB, Rodrigues NCP, Teixeira SAM, Villela LHC, et al. Prevalence of HTLV-1/2 in pregnant women living in the metropolitan area of Rio de Janeiro. PLoS Negl Trop Dis. Public Library of Science; 2014;8: e3146. pmid:25188386
- 23. Mello MA, da Conceição A, Sousa SM, Alcântara L, Marin L, Regina da Silva Raiol M, et al. HTLV-1 in pregnant women from the Southern Bahia, Brazil: a neglected condition despite the high prevalence. Virol J. 2014;11: 28. pmid:24524416
- 24. Sequeira CG, Tamegão-Lopes BP, Santos EJM Dos, Ventura AMR, Moraes-Pinto MI, Succi RC de M. Descriptive study of HTLV infection in a population of pregnant women from the state of Pará, Northern Brazil. Rev Soc Bras Med Trop. 45: 453–6. Available: http://www.ncbi.nlm.nih.gov/pubmed/22836660 pmid:22836660
- 25. Guimarães de Souza V, Lobato Martins M, Carneiro-Proietti AB de F, Januário JN, Ladeira RVP, Silva CMS, et al. High prevalence of HTLV-1 and 2 viruses in pregnant women in São Luis, state of Maranhão, Brazil. Rev Soc Bras Med Trop. 45: 159–62. Available: http://www.ncbi.nlm.nih.gov/pubmed/22534984 pmid:22534984
- 26. Machado Filho AC, Sardinha JFJ, Ponte RL, Costa EP da, da Silva SS, Martinez-Espinosa FE. Prevalence of infection for HIV, HTLV, HBV and of syphilis and chlamydia in pregnant women in a tertiary health unit in the western Brazilian Amazon region. Rev Bras Ginecol e Obs. Federação Brasileira das Sociedades de Ginecologia e Obstetrícia; 2010;32: 176–183.
- 27. Boa-Sorte N, Purificação A, Amorim T, Assunção L, Reis A, Galvão-Castro B. Dried blood spot testing for the antenatal screening of HTLV, HIV, syphilis, toxoplasmosis and hepatitis B and C: prevalence, accuracy and operational aspects. Brazilian J Infect Dis. 2014;18: 618–624. pmid:25022566
- 28. Magalhães T, Mota-Miranda AC, Alcantara LCJ, Olavarria V, Galvão-Castro B, Rios-Grassi MF. Phylogenetic and molecular analysis of HTLV-1 isolates from a medium sized town in Northern of Brazil: Tracing a common origin of the virus from the most endemic city in the country. J Med Virol. 2008;80: 2040–2045. pmid:18814252
- 29. Dal Fabbro MMFJ, Cunha RV da, Bóia MN, Portela P, Botelho CA, Freitas GMB de , et al. Infecção pelo HTLV 1/2: atuação no pré-natal como estratégia de controle da doença no Estado de Mato Grosso do Sul. Rev Soc Bras Med Trop. SBMT; 2008;41: 148–151. pmid:18545834
- 30. Figueiró-Filho EA, Senefonte FR de A, Lopes AHA, Morais OO de, Souza Júnior VG, Maia TL, et al. Freqüência das infecções pelo HIV-1, rubéola, sífilis, toxoplasmose, citomegalovírus, herpes simples, hepatite B, hepatite C, doença de Chagas e HTLV I/II em gestantes, do Estado de Mato Grosso do Sul. Rev Soc Bras Med Trop. SBMT; 2007;40: 181–187. pmid:17568885
- 31. Oliveira SR de, Avelino MM. Soroprevalência do vírus linfotrópico-T humano tipo I entre gestantes em Goiânia, GO, Brasil. Rev Bras Ginecol e Obs. 2006;28: 467–472.
- 32. Olbrich Neto J, Meira DA. [Soroprevalence of HTLV-I/II, HIV, siphylis and toxoplasmosis among pregnant women seen at Botucatu—São Paulo—Brazil: risk factors for HTLV-I/II infection]. Rev Soc Bras Med Trop. 37: 28–32. Available: http://www.ncbi.nlm.nih.gov/pubmed/15042179 pmid:15042179
- 33. Bittencourt AL, Dourado I, Filho PB, Santos M, Valadão E, Alcantara LC, et al. Human T-cell lymphotropic virus type 1 infection among pregnant women in northeastern Brazil. J Acquir Immune Defic Syndr. 2001;26: 490–4. Available: http://www.ncbi.nlm.nih.gov/pubmed/11391171 pmid:11391171
- 34. Broutet N, de Queiroz Sousa A, Basilio FP, Sa HL, Simon F, Dabis F. Prevalence of HIV-1, HIV-2 and HTLV antibody, in Fortaleza, Ceara, Brazil, 1993–1994. Int J STD AIDS. 1996;7: 365–369. pmid:8894828
- 35. dos Santos JI, Lopes MA, Deliège-Vasconcelos E, Couto-Fernandez JC, Patel BN, Barreto ML, et al. Seroprevalence of HIV, HTLV-I/II and other perinatally-transmitted pathogens in Salvador, Bahia. Rev Inst Med Trop Sao Paulo. 37: 343–8. Available: http://www.ncbi.nlm.nih.gov/pubmed/8599064 pmid:8599064
- 36. Casseb J. Is human T cell lymphotropic type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) syndrome a neglected disease? PLoS Negl Trop Dis. 2009;3: e487. pmid:19936247
- 37. Verdonck K, González E, Van Dooren S, Vandamme A-M, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis. 2007;7: 266–81. pmid:17376384
- 38. Gotuzzo E, Moody J, Verdonck K, Cabada MM, González E, Dooren S Van, et al. Frequent HTLV-1 infection in the offspring of Peruvian women with HTLV-1 –associated myelopathy / tropical spastic paraparesis or strongyloidiasis. 2007;22: 223–230.
- 39. Gascón MRP, Capitão CG, Casseb J, Nogueira-Martins MCF, Smid J, Oliveira ACP de. Prevalence of anxiety, depression and quality of life in HTLV-1 infected patients. Braz J Infect Dis. 15: 578–82. Available: http://www.ncbi.nlm.nih.gov/pubmed/22218518 pmid:22218518
- 40. Guiltinan AM, Kaidarova Z, Behan D, Marosi C, Hutching S, Kaiser M, et al. Major depression and generalized anxiety disorder among human T-lymphotropic virus types I- and II-infected former blood donors. Transfusion. 2013;53: 60–8. pmid:22554308
- 41. Galvão-Castro AV, Boa-Sorte N, Kruschewsky RA, Grassi MFR, Galvão-Castro B. Impact of depression on quality of life in people living with human T cell lymphotropic virus type 1 (HTLV-1) in Salvador, Brazil. Qual Life Res. 2012;21: 1545–50. pmid:22109110
- 42. Zihlmann KF, de Alvarenga AT, Casseb J. Living Invisible: HTLV-1-Infected Persons and the Lack of Care in Public Health. Kashanchi F, editor. PLoS Negl Trop Dis. 2012;6: e1705. pmid:22720112
- 43. Bhigjee AI, Moodley AA, Madurai S, York D, Bill PL. Infantile onset of HTLV-I-associated myelopathy (HAM/TSP). S Afr Med J. 1995;85: 687–8. Available: http://www.ncbi.nlm.nih.gov/pubmed/7482095 pmid:7482095
- 44. Oliveira PD, de Carvalho RF, Bittencourt AL. Adult T-cell leukemia/lymphoma in South and Central America and the Caribbean: systematic search and review. Int J STD AIDS. SAGE PublicationsSage UK: London, England; 2017;28: 217–228. pmid:28178905
- 45.
Montano SM, Zunt JR, Rodriguez L, Quispe I, Rodriguez C, Altamirano J, et al. Human T Cell Lymphotropic Virus Type 1 Infection and Early Neurologic Development: A Pilot Study of 48 Children [Internet]. 2004. Available: https://academic.oup.com/cid/article-abstract/39/7/1079/493178
- 46. Bittencourt AL, Primo J, Oliveira M de FP de. Manifestations of the human T-cell lymphotropic virus type I infection in childhood and adolescence. J Pediatr (Rio J). 2006;82: 411–420. pmid:17171202
- 47. Kendall EA, González E, Espinoza I, Tipismana M, Verdonck K, Clark D, et al. Early neurologic abnormalities associated with human T-cell lymphotropic virus type 1 infection in a cohort of Peruvian children. J Pediatr. NIH Public Access; 2009;155: 700–6. pmid:19628219
- 48. Maria Neves Varandas C, Lucas Sena da Silva J, Rita Primo JL, de Fátima de Oliveira MS, Moreno-Carvalho O, Farre L, et al. Clinical Infectious Diseases • CID 2018:XX (XX XXXX) • 1 Early Onset HAM/TSP With or Without IDH Early Juvenile Human T-cell Lymphotropic Virus Type-1-Associated Myelopathy/Tropical Spastic Paraparesis: Study of 25 Patients. Clin Infect Dis. 2018;
- 49. Kaplan JE, Osame M, Kubota H, Igata A, Nishitani H, Maeda Y, Khabbaz RF JR. The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. J Acquir Immune Defic Syndr. 1990;3: 1096–101. pmid:2213510
- 50. Satake M, Yamaguchi K, Tadokoro K. Current prevalence of HTLV-1 in Japan as determined by screening of blood donors. J Med Virol. 2012;84: 327–335. pmid:22170555
- 51. Martin F, Taylor GP, Jacobson S. Inflammatory manifestations of HTLV-1 and their therapeutic options. Expert Rev Clin Immunol. 2014;10: 1531–1546. pmid:25340428
- 52. Mendes MST, Costa MC, Costa IMC, Mendes MST, Costa MC, Costa IMC. Human T-cell lymphotropic virus-1 infection: three infected generations in the same family. Rev Soc Bras Med Trop. SBMT; 2016;49: 660–662. pmid:27812668
- 53. Bandeira LM, Uehara SNO, Puga MAM, Rezende GR, Vicente ACP, Domingos JA, et al. HTLV-1 intrafamilial transmission among Japanese immigrants in Brazil. J Med Virol. 2017; pmid:28876483
- 54. Costa CA da, Furtado KCYO, Ferreira L de SC, Almeida D de S, Linhares A da C, Ishak R, et al. Familial Transmission of Human T-cell Lymphotrophic Virus: Silent Dissemination of an Emerging but Neglected Infection. Kashanchi F, editor. PLoS Negl Trop Dis. 2013;7: e2272. pmid:23785534
- 55.
Antônio M, Mello G, Ferreira Da Conceição A, Mara S, Sousa B, Alcântara LC, et al. HTLV-1 in pregnant women from the Southern Bahia, Brazil: a neglected condition despite the high prevalence. 2014; https://doi.org/10.1186/1743-422X-11-28
- 56. Percher F, Jeannin P, Martin-Latil S, Gessain A, Afonso P V, Vidy-Roche A, et al. Mother-to-Child Transmission of HTLV-1 Epidemiological Aspects, Mechanisms and Determinants of Mother-to-Child Transmission. pmid:26848683
- 57. Nerome Y, Kojyo K, Ninomiya Y, Ishikawa T, Ogiso A, Takei S, et al. Current human T-cell lymphotropic virus type 1 mother-to-child transmission prevention status in Kagoshima. Pediatr Int. 2014;56: 640–643. pmid:25252059
- 58. van Tienen C, Jakobsen M, Schim van der Loeff M. Stopping breastfeeding to prevent vertical transmission of HTLV-1 in resource-poor settings: beneficial or harmful? Arch Gynecol Obstet. Springer; 2012;286: 255–6. pmid:22228317
- 59.
Ministério da Saúde do Brasil. Dia de Conscientização da Fibrose Cística é celebrado em todo o País—Portal Brasil [Internet]. 2013 [cited 21 Aug 2017]. Available: http://www.brasil.gov.br/saude/2013/09/dia-de-conscientizacao-da-fibrose-cistica-e-celebrado-em-todo-o-pais
- 60. Monteiro LTB, Cândido LMB. Fenilcetonúria no Brasil: evolução e casos. Rev Nutr. Revista de Nutrição; 2006;19: 381–387.